Florouquinolone sensitivity in conjunctival flora in preoperative cataract surgery in a tertiary care hospital in Chennai, South India
Session Details
Session Title: Infections
Session Date/Time: Sunday 23/09/2018 | 16:30-18:00
Paper Time: 16:42
Venue: Room A3, Podium 3
First Author: : M.Lakshmipathy INDIA
Co Author(s): : L. Therese
Abstract Details
Purpose:
To study the invitro susceptibility of conjunctival flora to routinely used topical floroquinolones prior to elective cataract surgery in one eyed patients
Setting:
Department of Cornea and Refractive surgery.Medical Research Foundation, Chennai
Methods:
Retrospective analysis of data of four and a half years (Jan 2013-June 2017) by standard methods of bacterial isolation and antibiogram by Kirby Bauer disk diffusion method. Patients underwent conjunctival swab test within 2 weeks of planned cataract surgery.
Results:
Total isolates included 1150 of 812 patients. Gram positive cultures was 89.9% and gram negative was 10.1%. The flouroquinolones which showed maximum susceptibility to gram positive organism included moxifloxacin(88,27%) and gatifloxacin (81.67%). Gram negative organism were 94.78% susceptible to ciprofloxacin and 93.88% to gatifloxacin.Comparing the resistance between ciprofloxacin, gatifloaxcin and moxifloxacin, ciprofloxacin showed maximum resistance to both gram positive and negative bacteria.Gatifloxacin showed 18.3% resistance to gram positive and moxifloxacin showed 14% resistance to gram negative organisms. The commonest isolate Coagulase negative staphylococci CONS(54.1%) showed better susptibilty to moxifloxacin 90.66% than gatifloxacin 79.90%.Norfloxacin and ofloxacin shwed reduced sensitivity overall.
Conclusions:
Use of topical flouroquinolones needs caution due to the increasing resistance pattern to gatifloxacin in gram positive and moxifloxacin in gram negative bacterial isolates of conjunctival flora. Normal conjunctival flora shows less susceptibility to ciprofloxacin indicating indiscriminate use as a risk factor for resistance in the community
Financial Disclosure:
-